Role of Activating Transcription Factor 4 in Murine Choroidal Neovascularization Model.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
18 Aug 2021
Historique:
received: 29 07 2021
revised: 17 08 2021
accepted: 17 08 2021
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 21 9 2021
Statut: epublish

Résumé

Neovascular age-related macular degeneration (nAMD) featuring choroidal neovascularization (CNV) is the principal cause of irreversible blindness in elderly people in the world. Integrated stress response (ISR) is one of the intracellular signals to be adapted to various stress conditions including endoplasmic reticulum (ER) stress. ISR signaling results in the upregulation of activating transcription factor 4 (ATF4), which is a mediator of ISR. Although recent studies have suggested ISR contributes to the progression of some age-related disorders, the effects of ATF4 on the development of CNV remain unclear. Here, we performed a murine model of laser-induced CNV and found that ATF4 was highly expressed in endothelial cells of the blood vessels of the CNV lesion site. Exposure to integrated stress inhibitor (ISRIB) reduced CNV formation, vascular leakage, and the upregulation of vascular endothelial growth factor (VEGF) in retinal pigment epithelium (RPE)-choroid-sclera complex. In human retinal microvascular endothelial cells (HRMECs), ISRIB reduced the level of ATF4 and VEGF induced by an ER stress inducer, thapsigargin, and recombinant human VEGF. Moreover, ISRIB decreased the VEGF-induced cell proliferation and migration of HRMECs. Collectively, our findings showed that pro-angiogenic effects of ATF4 in endothelial cells may be a potentially therapeutic target for patients with nAMD.

Identifiants

pubmed: 34445595
pii: ijms22168890
doi: 10.3390/ijms22168890
pmc: PMC8396241
pii:
doi:

Substances chimiques

Atf4 protein, mouse 0
Vascular Endothelial Growth Factors 0
Activating Transcription Factor 4 145891-90-3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Invest Ophthalmol Vis Sci. 2013 Sep 03;54(9):5995-6002
pubmed: 23942974
Elife. 2020 Dec 01;9:
pubmed: 33258451
Prog Retin Eye Res. 2021 May;82:100906
pubmed: 33022379
Mol Cell. 2021 Jan 7;81(1):88-103.e6
pubmed: 33220178
Blood. 2008 Jul 15;112(2):330-9
pubmed: 18451308
PLoS One. 2013;8(3):e60517
pubmed: 23544152
J Bone Miner Res. 2013 Sep;28(9):1870-1884
pubmed: 23649506
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Drug Des Devel Ther. 2016 Jun 02;10:1857-67
pubmed: 27330279
Biochem Biophys Res Commun. 2020 Dec 17;533(4):1406-1412
pubmed: 33092793
Biochem Biophys Res Commun. 2007 Mar 16;354(3):707-11
pubmed: 17254549
Ann Clin Transl Neurol. 2019 Aug;6(8):1407-1422
pubmed: 31402619
Nat Commun. 2020 Nov 5;11(1):5594
pubmed: 33154371
Mol Vis. 2016 Feb 03;22:116-28
pubmed: 26900328
Science. 2020 Apr 24;368(6489):
pubmed: 32327570
Rom J Ophthalmol. 2015 Apr-Jun;59(2):74-7
pubmed: 26978865
Curr Eye Res. 2017 Aug;42(8):1202-1208
pubmed: 28497987
Am J Pathol. 2012 Aug;181(2):376-9
pubmed: 22749677
EMBO Rep. 2016 Oct;17(10):1374-1395
pubmed: 27629041
Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12741-6
pubmed: 16912112
Cell Mol Life Sci. 2013 Oct;70(19):3493-511
pubmed: 23354059
Elife. 2013 May 28;2:e00498
pubmed: 23741617
J Exp Med. 2008 May 12;205(5):1227-42
pubmed: 18458112
Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23705-23713
pubmed: 31685620
Cell Death Dis. 2015 Mar 05;6:e1672
pubmed: 25741597
Cell Death Dis. 2020 May 26;11(5):397
pubmed: 32457286
J Biol Chem. 2011 Jun 10;286(23):20991-1001
pubmed: 21515678
Mol Cell. 2014 May 22;54(4):559-72
pubmed: 24746698
Mol Cell. 2000 Nov;6(5):1099-108
pubmed: 11106749
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3747-3754
pubmed: 30046816
Sci Rep. 2015 Apr 30;5:9898
pubmed: 25927172
Exp Eye Res. 2016 May;146:196-205
pubmed: 27018216
Mol Med. 2010 Nov-Dec;16(11-12):535-42
pubmed: 20683548
Invest Ophthalmol Vis Sci. 1996 Apr;37(5):855-68
pubmed: 8603870
Vision Res. 1985;25(1):21-31
pubmed: 3984214
J Inflamm (Lond). 2015 Apr 17;12:31
pubmed: 25914608
Graefes Arch Clin Exp Ophthalmol. 2004 Sep;242(9):777-83
pubmed: 15103470
Neoplasia. 2013 Aug;15(8):989-97
pubmed: 23908598
J Neurosci. 2018 Jan 17;38(3):648-658
pubmed: 29196323
Clin Interv Aging. 2008;3(3):473-82
pubmed: 18982917
Endocr Rev. 2004 Aug;25(4):581-611
pubmed: 15294883
Mol Cell. 2018 Aug 16;71(4):629-636.e5
pubmed: 30118681
Br J Ophthalmol. 2014 Sep;98(9):1144-67
pubmed: 25136079
Invest Ophthalmol Vis Sci. 1996 Aug;37(9):1929-34
pubmed: 8759365
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Curr Eye Res. 2006 Dec;31(12):1051-61
pubmed: 17169844
Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2599-605
pubmed: 18296663
BMC Ophthalmol. 2020 Jan 8;20(1):15
pubmed: 31914968
Nat Commun. 2015 Aug 11;6:7847
pubmed: 26260587
Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):39
pubmed: 33252634
J Histochem Cytochem. 2017 May;65(5):285-294
pubmed: 28438094
BMC Syst Biol. 2013 Jan 22;7:9
pubmed: 23339444
Cancer Res. 2012 Oct 15;72(20):5396-406
pubmed: 22915762

Auteurs

Hiroto Yasuda (H)

Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu 501-1196, Japan.

Miruto Tanaka (M)

Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu 501-1196, Japan.

Anri Nishinaka (A)

Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu 501-1196, Japan.

Shinsuke Nakamura (S)

Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu 501-1196, Japan.

Masamitsu Shimazawa (M)

Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu 501-1196, Japan.

Hideaki Hara (H)

Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu 501-1196, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH